NCT03983577招募中不适用
Efficacy of Point Of Service Testing in Metastatic Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Proportion of patients/participants that undergo hereditary cancer genetic testing after the telehealth intervention.
研究概览
简要总结
This study will assess the efficacy of an innovative point of service cancer genetics counseling delivery model for metastatic breast cancer (MBC) patients whom have received a referral for hereditary cancer genetic counseling and testing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent.
- •Able to speak and read in the English language.
- •Have a diagnosis of human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer.
- •Participants must be enrolled in the parent registry study.
排除标准
- •Genetic testing for a breast cancer gene (BRCA) BRCA1 and BRCA2 mutation completed after 2013 or any BRCA 1 and BRCA2 testing with large rearrangement testing. Prior genetic counseling is allowed.
- •Psychiatric illness/social situations that would limit compliance with study requirements.
结局指标
主要结局
Proportion of patients/participants that undergo hereditary cancer genetic testing after the telehealth intervention.
时间窗: 24 months
Defined as the number of participants who opt to undergo hereditary cancer genetic testing as a percentage of the total number of participants enrolled.
次要结局
- Clinical decisional conflict score(24 months)
- Overall participant satisfaction(24 months)
- Overall participant anxiety(24 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Genetic Testing for All Breast Cancer Patients (GET FACTS)In Situ Breast CancerGenetic TestingBreast Cancerin Situ Breast CancerInvasive Breast CancerNCT04245176Brigham and Women's Hospital400
招募中
2 期
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialCastration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8NCT06632977Alliance for Clinical Trials in Oncology474
已完成
不适用
The Signal-Trial: Evaluation of a Screening Tool for Psychosocial Problems in Cancer GeneticsPsychosocial IssuesCancer GeneticsNCT01562431The Netherlands Cancer Institute246
进行中（未招募）
不适用
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient OutcomesPancreas CancerProstate CancerOvarian CancerNCT02917798Memorial Sloan Kettering Cancer Center1,047
招募中
不适用
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test ResultsBRCA1 MutationPOLD1 Gene MutationCDKN2A MutationBRCA2 MutationPOLE Gene MutationAPC Gene MutationATM Gene MutationMLH1 Gene MutationBARD1 Gene MutationMSH2 Gene MutationBRIP1 Gene MutationMSH6 Gene MutationCHEK2 Gene MutationPMS2 Gene MutationPALB2 Gene MutationEPCAM Gene MutationRAD51C Gene MutationBMPR1A Gene MutationRAD51D Gene MutationSMAD4PTEN Gene MutationGREM1NCT05420064Memorial Sloan Kettering Cancer Center1,000